Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acoltremon 0.003% for Dry Eye Disease in Contact Lens Wearers
NCT07848373Phase 4Not yet recruiting
- Sponsor
- Eye Research Associates
- Start
- Oct 2026
- Primary completion
- Feb 2027
01
Overview
Phase 4, open-label, single-arm trial of acoltremon in dry eye disease (DED), sponsored by Eye Research Associates. Primary endpoint: Eye Dryness Visual Analog Scale Score at 4 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
acoltremon
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT07848373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07848373.